NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's ...

We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. In this article, we are going to take a look at where NeoGenomics, Inc. (NASDAQ:NEO) stands against the other ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below offers a condensed view of ...

NeoGenomics (NASDAQ:NEO) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement. Analysts estimate that NeoGenomics will ...

Throughout its cycle, NEO has aligned closely with the Adhishthana Principles, our proprietary model that blends behavioral archetypes with quantitative signals. One of the best examples of this was ...

NeoGenomics (NASDAQ:NEO) shares plunged on Tuesday after the cancer lab operator reported lower-than-expected revenue for Q1 2025 as its topline contracted sequentially for the first time since late ...

Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Strategic Financial Concepts LLC acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The ...